Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.40 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.40 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.40 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.39 |
| ▸ | LPAR1 | Q92633 | 6/20 | 0.38 |
| ▸ | PPARG | P37231 | 2/20 | 0.38 |
| ▸ | PPARA | Q07869 | 2/20 | 0.38 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | LPAR5 | Q9H1C0 | 2/20 | 0.37 |
| ▸ | LPAR2 | Q9HBW0 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16991895 | 0.92 | MEN1 (0.46) | MEN1KMT2AL3MBTL1GAAHPGD | |
| SCHEMBL16991900 | 0.85 | L3MBTL1 (0.47) | MEN1KMT2AL3MBTL1GAAHPGD | |
| SCHEMBL16991959 | 0.81 | CHEK1 (0.44) | — | |
| SCHEMBL16991957 | 0.81 | CHEK1 (0.44) | — | |
| SCHEMBL16992104 | 0.77 | HDAC3 (0.50) | MEN1KMT2AL3MBTL1GAAHPGD | |
| SCHEMBL9823156 | 0.76 | HDAC1 (0.54) | MEN1KMT2AL3MBTL1HDAC1HDAC3 | |
| SCHEMBL16991891 | 0.74 | MEN1 (0.39) | MEN1KMT2AGAAHPGD | |
| SCHEMBL17002502 | 0.73 | MEN1 (0.50) | MEN1KMT2AL3MBTL1HPGDHDAC1 | |
| SCHEMBL1797681 | 0.73 | HDAC1 (0.50) | MEN1KMT2AL3MBTL1HDAC1HDAC3 | |
| SCHEMBL3695642 | 0.73 | HDAC1 (0.55) | L3MBTL1HDAC1HDAC3HDAC2NCOR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11786524-B2 | Pharmaceutical compounds | SENTINEL ONCOLOGY LIMITED (GB) | 2023-10-17 | — | — | US | disclosed |
| US-11786524-B2 | Pharmaceutical compounds | SENTINEL ONCOLOGY LIMITED (GB) | 2023-10-17 | — | — | US | disclosed |
| US-20210275525-A1 | PHARMACEUTICAL COMPOUNDS | SENTINEL ONCOLOGY LIMITED (GB) | 2021-09-09 | — | — | US | disclosed |
| EP-3811944-A1 | PHARMACEUTICAL COMPOUNDS AS CHK1 INHIBITORS | Sentinel Oncology Limited (GB) | 2021-04-28 | — | — | EP | disclosed |
| EP-3811944-A1 | PHARMACEUTICAL COMPOUNDS AS CHK1 INHIBITORS | Sentinel Oncology Limited (GB) | 2021-04-28 | — | — | EP | disclosed |
| US-10973817-B2 | Pharmaceutical compounds | SENTINEL ONCOLOGY LIMITED (GB) | 2021-04-13 | — | — | US | disclosed |
| EP-3104860-B1 | PHARMACEUTICAL COMPOUNDS AS CHK1 INHIBITORS | SENTINEL ONCOLOGY LTD (GB) | 2020-12-30 | — | — | EP | disclosed |
| EP-3104860-B1 | PHARMACEUTICAL COMPOUNDS AS CHK1 INHIBITORS | SENTINEL ONCOLOGY LTD (GB) | 2020-12-30 | — | — | EP | disclosed |
| US-20180271860-A1 | PHARMACEUTICAL COMPOUNDS | CASCADIAN THERAPEUTICS, INC. (US) | 2018-09-27 | — | — | US | disclosed |
| US-10010547-B2 | Pharmaceutical compounds | CASCADIAN THERAPEUTICS, INC. (US) | 2018-07-03 | — | — | US | disclosed |
| US-10010547-B2 | Pharmaceutical compounds | CASCADIAN THERAPEUTICS, INC. (US) | 2018-07-03 | — | — | US | disclosed |
| EP-3104860-A1 | PHARMACEUTICAL COMPOUNDS | Cascadian Therapeutics, Inc. (US) | 2016-12-21 | — | — | EP | disclosed |
| US-20160361310-A1 | PHARMACEUTICAL COMPOUNDS | SEATTLE GENETICS, INC. | 2016-12-15 | — | — | US | disclosed |
| US-20160361310-A1 | PHARMACEUTICAL COMPOUNDS | SEATTLE GENETICS, INC. | 2016-12-15 | — | — | US | disclosed |
| US-20160361310-A1 | PHARMACEUTICAL COMPOUNDS | SEATTLE GENETICS, INC. | 2016-12-15 | — | — | US | disclosed |
| WO-2015120390-A1 | PHARMACEUTICAL COMPOUNDS | ONCOTHYREON INC. (US) | 2015-08-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10010547-B2 | Pharmaceutical compounds | CHKA, CHKB, TNK2 | MEN1 1383/4885KMT2A 2862/4885L3MBTL1 4088/4885 |
| US-20180271860-A1 | PHARMACEUTICAL COMPOUNDS | CHKA, CHKB, TNK2 | MEN1 1383/4885KMT2A 2862/4885L3MBTL1 4088/4885 |
| US-11786524-B2 | Pharmaceutical compounds | CHKA, CHKB, TNK2 | MEN1 1383/4885KMT2A 2862/4885L3MBTL1 4088/4885 |
| US-20160361310-A1 | PHARMACEUTICAL COMPOUNDS | CHKA, CHKB, TNK2 | MEN1 1383/4885KMT2A 2862/4885L3MBTL1 4088/4885 |
| US-20210275525-A1 | PHARMACEUTICAL COMPOUNDS | CHKA, CHKB, TNK2 | MEN1 1383/4885KMT2A 2862/4885L3MBTL1 4088/4885 |
| US-10973817-B2 | Pharmaceutical compounds | CHKA, CHKB, TNK2 | MEN1 1383/4885KMT2A 2862/4885L3MBTL1 4088/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.